Astellas Pharma Inc. (“Astellas”; President and CEO: Masafumi Nogimori) announced today that it has decided to dissolve its European subsidiary, Fujisawa Ireland Ltd. (headquarters: Kerry, Ireland).
1. Reasons for the dissolution
Astellas was created as a result of the merger of the former Yamanouchi Pharmaceutical Co., Ltd. and the former Fujisawa Pharmaceutical Co., Ltd. on April 1, 2005. Astellas has decided to dissolve Fujisawa Ireland Ltd. because the transfer of its functions to Astellas Ireland Co., Ltd., which was established in October 2005 as Astellas’s production subsidiary in Europe, has been completed.
2. Outline of the subsidiary to be dissolved
(As of March 31, 2008)
| 1) Company name | Fujisawa Ireland Ltd. |
| 2) Business | Manufacturing and marketing of pharmaceuticals |
| 3) Date of establishment | September 1990 |
| 4) Location | Killorglin, Co Kerry, Ireland |
| 5) Representative |
Mitsuhiro Matsuda |
| 6) Capital | *€2,172,093 |
| 7) Total shares outstanding | *1,710,000 shares |
| 8) Shareholders' equity | *€2,223,107 |
| 9) Total assets | *€2,223,107 |
| 10) Fiscal year end | March 31 |
| 11) Number of employee | 1 |
| 12) Major customers and suppliers | Astellas Pharma Inc. |
| 13) Major shareholders (%) | Astellas B.V. (100%) |
*Figures as of July 31, 2008
3. Financial impacts of the dissolution
The dissolution will have no impact on Astellas’s business performance.
4. Schedule for dissolution
The winding-up has been resolved at the extraordinary general meeting of Fujisawa Ireland Ltd. on September 29, 2008 (local time).
*The date of dissolution has not yet been decided.
